Literature DB >> 12151656

Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction.

G R Rhydwen1, S Charman, P M Schofield.   

Abstract

BACKGROUND: Post-myocardial infarction ventricular septal defect (VSD) complicates approximately 2% of myocardial infarctions. Thrombolytic therapy may accelerate the time from myocardial infarction to VSD formation. The effects of thrombolytic therapy in patients with a post-myocardial infarction VSD were investigated.
METHOD: Demographic, procedural, and event data were retrospectively analysed in patients transferred to a regional cardiothoracic centre with the diagnosis of post-myocardial infarction VSD over five years.
RESULTS: Twenty nine patients were analysed; 15 received thrombolytic therapy: 10 (<12 hours) early and five (> or =12 hours) late. The median time to post-myocardial infarction VSD was shorter with thrombolytic therapy at 1 v 5.5 days (p=0.01). The median time to post-myocardial infarction VSD was shorter with early compared with late thrombolytic therapy at 1 v 6 days (p<0.01). There was no difference between late and no thrombolytic therapy, 5.5 v 6 days. Patients treated with thrombolytic therapy had a trend towards higher mortality at 11/15 (73%) compared with 5/14 (36%) (p=0.066). Twenty five (86%) patients had surgery. All four not having surgery died. Surgical survival was 13/25 (52%) at discharge and six months of follow up. Within the surgical group survival with prior thrombolytic therapy was 4/25 (25%) and 9/13 (69%) without (p=0.07).
CONCLUSION: There appears to be an earlier presentation of post-myocardial infarction VSD when thrombolytic therapy has been used. An early presentation can carry a worse prognosis and may have implications for the identification and treatment of this life threatening complication.

Entities:  

Mesh:

Year:  2002        PMID: 12151656      PMCID: PMC1742442          DOI: 10.1136/pmj.78.921.408

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  31 in total

1.  Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect.

Authors:  R G Cummings; K A Reimer; R Califf; D Hackel; J Boswick; J E Lowe
Journal:  Circulation       Date:  1988-01       Impact factor: 29.690

2.  Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.

Authors:  B S Crenshaw; C B Granger; Y Birnbaum; K S Pieper; D C Morris; N S Kleiman; A Vahanian; R M Califf; E J Topol
Journal:  Circulation       Date:  2000 Jan 4-11       Impact factor: 29.690

3.  Transmural, haemorrhagic myocardial infarction after intracoronary streptokinase. Clinical, angiographic, and necropsy findings.

Authors:  D G Mathey; J Schofer; K H Kuck; U Beil; G Klöppel
Journal:  Br Heart J       Date:  1982-12

4.  Urgent surgical repair of postinfarction ventricular septal rupture: early and late outcome.

Authors:  F Bouchart; J P Bessou; A Tabley; M Redonnet; D Mouton-Schleifer; C Haas-Hubscher; R Soyer
Journal:  J Card Surg       Date:  1998-03       Impact factor: 1.620

5.  A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase.

Authors:  H Fujiwara; T Onodera; M Tanaka; T Fujiwara; D J Wu; C Kawai; Y Hamashima
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

6.  Ventricular septal rupture complicating acute myocardial infarction: identification of simple and complex types in 53 autopsied hearts.

Authors:  B S Edwards; W D Edwards; J E Edwards
Journal:  Am J Cardiol       Date:  1984-12-01       Impact factor: 2.778

7.  Myocardial rupture after acute myocardial infarction. Ten year review.

Authors:  M P Feneley; V P Chang; M F O'Rourke
Journal:  Br Heart J       Date:  1983-06

8.  Cardiac rupture in patients with acute myocardial infarction.

Authors:  I Shapira; A Isakov; M Burke; C Almog
Journal:  Chest       Date:  1987-08       Impact factor: 9.410

9.  Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival.

Authors:  C A Moore; T W Nygaard; D L Kaiser; A A Cooper; R S Gibson
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

Review 10.  Ventricular septal rupture: a review of clinical and physiologic features and an analysis of survival.

Authors:  M J Radford; R A Johnson; W M Daggett; J T Fallon; M J Buckley; H K Gold; R C Leinbach
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

View more
  5 in total

Review 1.  Optimal management of acute ventricular septal rupture.

Authors:  Andrew Murday
Journal:  Heart       Date:  2003-12       Impact factor: 5.994

2.  Delayed ventricular septal rupture after percutaneous coronary intervention in acute myocardial infarction.

Authors:  Ji Young Park; Seong Hoon Park; Ji Young Oh; In Je Kim; Yu Hyun Lee; Si Hoon Park; Ki Hwan Kwon
Journal:  Korean J Intern Med       Date:  2005-09       Impact factor: 2.884

3.  Effect of thrombolytic therapy on the patterns of post myocardial infarction ventricular septal rupture.

Authors:  Sunil Kumar Srinivas; Bharathi Sunil; Prabhavathi Bhat; Cholenahally Nanjappa Manjunath
Journal:  Indian Heart J       Date:  2017-04-01

4.  Early thrombolysis is associated with decreased operative mortality in postinfarction ventricular septal rupture.

Authors:  Neeti Dogra; Goverdhan Dutt Puri; Shyam K S Thingnam; V K Arya; Bhupesh Kumar; Sachin Mahajan; Madhur Verma
Journal:  Indian Heart J       Date:  2019-05-03

5.  Decision making, management, and midterm outcomes of postinfarction ventricular septal rupture: Our experience with 21 patients.

Authors:  Samarjit Bisoyi; Usha Jagannathan; Anjan K Dash; Raghunath Mohapatra; Debashish Nayak; Satyajit Sahu; Pattnaik Satyanarayan
Journal:  Ann Card Anaesth       Date:  2020 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.